It is heartening that the Union Budget 2022 identifies Genomics and Pharmaceuticals as ‘sunrise’ sectors: Boehringer Ingelheim India

February 01, 2022 | Tuesday | Views

Vani Manja, Country Managing Director, Boehringer Ingelheim India

“It is heartening that the Union Budget 2022 identifies Genomics and Pharmaceuticals as ‘sunrise’ sectors. This would enable well-rounded development beyond employment and access to enhanced industry efficiencies and competitiveness, which will go a long way in attracting increased investments in biopharmaceutical innovation. Our progress in research and development is inextricably linked to fostering a culture of innovation. Allowing for additional provisions towards establishing a stronger IPR ecosystem in the country is imperative to improve the Ease of Doing Index in India and further propel FDI in the pharmaceutical sector."


Comments

× Your session has expired. Please click here to Sign-in or Sign-up

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy